Answers are grounded in this paper and cite their sources.
Lenvatinib, a multi-kinase inhibitor targeting VEGFR 1–3 and FGFR 1–4, is a first-line therapy for unresectable hepatocellular carcinoma (HCC). While palmar-plantar erythrodysesthesia and generalized erythematous rashes are recognized side effects, lenvatinib-induced lichenoid drug reactions (LDRs) remain infrequently reported and pose significant diagnostic challenges when presenting as viral exanthematous mimics. This case describes an 82-year-old female with metastatic HCC who developed a generalized, pruritic, and vesicular rash mimicking disseminated herpes zoster shortly after initiating lenvatinib. Despite prior shingles vaccination, empiric intravenous acyclovir was initiated. A skin biopsy revealed a lichenoid dermatitis with Civatte bodies and significant eosinophilia, confirming an LDR. The eruption resolved following systemic corticosteroid therapy, indicating a likely reaction to recent lenvatinib exposure. This case highlights the importance of histopathological verification and chronological drug reconciliation in differentiating drug-induced dermatotoxicity from viral exanthems in fragile oncology populations.
No takes yet. Share an insight, caveat, or question.
Kaufman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: